Global Infectious Disease Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Infectious Disease Therapeutics Market:
Global infectious disease therapeutics market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for infectious disease therapeutics is projected to reach US$ XX Mn by 2023.
Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases transmitted from one individual to other either by direct or indirect contact. The drugs used for the infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others.
Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.
Infectious disease therapeutics market segmented based on drug class, disease indication, and distribution channel
Based on drug class, infectious disease therapeutics market is segmented into
Geographically infectious disease therapeutics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infectives has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry along with government initiative to boost biotechnology sector of the respective country are fuelling the growth of the infectious disease therapeutics market in Asia Pacific region.
Some of the players in infectious disease therapeutics market are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Auritec Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), Sanofi S.A. (France) and Gilead Sciences (U.S.) to name a few.
In July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus
In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections
In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.
REPORT OUTLINE:
Global infectious disease therapeutics market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for infectious disease therapeutics is projected to reach US$ XX Mn by 2023.
Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases transmitted from one individual to other either by direct or indirect contact. The drugs used for the infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others.
Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.
Infectious disease therapeutics market segmented based on drug class, disease indication, and distribution channel
Based on drug class, infectious disease therapeutics market is segmented into
- Anti-Bacterial
- Anti-Viral
- Anti-Parasite
- Anti-Fungal
- Others
- HIV/AIDS
- Influenza
- Hepatitis
- Malaria
- TB
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Others
Geographically infectious disease therapeutics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infectives has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry along with government initiative to boost biotechnology sector of the respective country are fuelling the growth of the infectious disease therapeutics market in Asia Pacific region.
Some of the players in infectious disease therapeutics market are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Auritec Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), Sanofi S.A. (France) and Gilead Sciences (U.S.) to name a few.
In July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus
In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections
In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.
REPORT OUTLINE:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET INTRODUCTION
2.1. Global Infectious Disease Therapeutics Market– Taxonomy
2.2. Global Infectious Disease Therapeutics Market– Definitions
2.2.1. Drug Class
2.2.2. Disease Indication
3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Infectious Disease Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Infectious Disease Therapeutics Market– Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Anti-Bacterial
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Anti-Viral
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Anti-Parasite
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Anti-Fungal
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. HIV/AIDS
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Influenza
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Hepatitis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Malaria
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Tuberculosis (TB)
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Anti-Bacterial
9.1.1.2. Anti-Viral
9.1.1.3. Anti-Parasite
9.1.1.4. Anti-Fungal
9.1.1.5. Others
9.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. HIV/AIDS
9.1.2.2. Influenza
9.1.2.3. Hepatitis
9.1.2.4. Malaria
9.1.2.5. TB
9.1.2.6. Others
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Infectious Disease Therapeutics Market Dynamics – Trends
10. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Anti-Bacterial
10.1.1.2. Anti-Viral
10.1.1.3. Anti-Parasite
10.1.1.4. Anti-Fungal
10.1.1.5. Others
10.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. HIV/AIDS
10.1.2.2. Influenza
10.1.2.3. Hepatitis
10.1.2.4. Malaria
10.1.2.5. TB
10.1.2.6. Others
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Infectious Disease Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Anti-Bacterial
11.1.1.2. Anti-Viral
11.1.1.3. Anti-Parasite
11.1.1.4. Anti-Fungal
11.1.1.5. Others
11.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. HIV/AIDS
11.1.2.2. Influenza
11.1.2.3. Hepatitis
11.1.2.4. Malaria
11.1.2.5. TB
11.1.2.6. Others
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
11.1.6. Asia-Pacific Infectious Disease Therapeutics Market Dynamics – Trends
12. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Anti-Bacterial
12.1.1.2. Anti-Viral
12.1.1.3. Anti-Parasite
12.1.1.4. Anti-Fungal
12.1.1.5. Others
12.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. HIV/AIDS
12.1.2.2. Influenza
12.1.2.3. Hepatitis
12.1.2.4. Malaria
12.1.2.5. TB
12.1.2.6. Others
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Infectious Disease Therapeutics Market Dynamics – Trends
13. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Anti-Bacterial
13.1.1.2. Anti-Viral
13.1.1.3. Anti-Parasite
13.1.1.4. Anti-Fungal
13.1.1.5. Others
13.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. HIV/AIDS
13.1.2.2. Influenza
13.1.2.3. Hepatitis
13.1.2.4. Malaria
13.1.2.5. TB
13.1.2.6. Others
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Infectious Disease Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GlaxoSmithKline Plc (U.K.)
14.2.2. Johnson & Johnson Services, Inc. (U.S.)
14.2.3. Merck & Co, Inc. (U.S.)
14.2.4. Pfizer Inc. (U.S.)
14.2.5. Novartis AG. (Switzerland)
14.2.6. AbbVie Inc. (U.S.)
14.2.7. Astellas Pharma Inc. (Japan)
14.2.8. AstraZeneca (U.K.)
14.2.9. Auritec Pharmaceuticals Inc. (U.S.)
14.2.10. Bayer AG (Germany)
14.2.11. Chimerix Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET INTRODUCTION
2.1. Global Infectious Disease Therapeutics Market– Taxonomy
2.2. Global Infectious Disease Therapeutics Market– Definitions
2.2.1. Drug Class
2.2.2. Disease Indication
3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Infectious Disease Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Infectious Disease Therapeutics Market– Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Anti-Bacterial
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Anti-Viral
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Anti-Parasite
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Anti-Fungal
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. HIV/AIDS
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Influenza
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Hepatitis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Malaria
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Tuberculosis (TB)
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Anti-Bacterial
9.1.1.2. Anti-Viral
9.1.1.3. Anti-Parasite
9.1.1.4. Anti-Fungal
9.1.1.5. Others
9.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. HIV/AIDS
9.1.2.2. Influenza
9.1.2.3. Hepatitis
9.1.2.4. Malaria
9.1.2.5. TB
9.1.2.6. Others
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Infectious Disease Therapeutics Market Dynamics – Trends
10. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Anti-Bacterial
10.1.1.2. Anti-Viral
10.1.1.3. Anti-Parasite
10.1.1.4. Anti-Fungal
10.1.1.5. Others
10.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. HIV/AIDS
10.1.2.2. Influenza
10.1.2.3. Hepatitis
10.1.2.4. Malaria
10.1.2.5. TB
10.1.2.6. Others
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Infectious Disease Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Anti-Bacterial
11.1.1.2. Anti-Viral
11.1.1.3. Anti-Parasite
11.1.1.4. Anti-Fungal
11.1.1.5. Others
11.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. HIV/AIDS
11.1.2.2. Influenza
11.1.2.3. Hepatitis
11.1.2.4. Malaria
11.1.2.5. TB
11.1.2.6. Others
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
11.1.6. Asia-Pacific Infectious Disease Therapeutics Market Dynamics – Trends
12. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Anti-Bacterial
12.1.1.2. Anti-Viral
12.1.1.3. Anti-Parasite
12.1.1.4. Anti-Fungal
12.1.1.5. Others
12.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. HIV/AIDS
12.1.2.2. Influenza
12.1.2.3. Hepatitis
12.1.2.4. Malaria
12.1.2.5. TB
12.1.2.6. Others
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Infectious Disease Therapeutics Market Dynamics – Trends
13. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Anti-Bacterial
13.1.1.2. Anti-Viral
13.1.1.3. Anti-Parasite
13.1.1.4. Anti-Fungal
13.1.1.5. Others
13.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. HIV/AIDS
13.1.2.2. Influenza
13.1.2.3. Hepatitis
13.1.2.4. Malaria
13.1.2.5. TB
13.1.2.6. Others
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Infectious Disease Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GlaxoSmithKline Plc (U.K.)
14.2.2. Johnson & Johnson Services, Inc. (U.S.)
14.2.3. Merck & Co, Inc. (U.S.)
14.2.4. Pfizer Inc. (U.S.)
14.2.5. Novartis AG. (Switzerland)
14.2.6. AbbVie Inc. (U.S.)
14.2.7. Astellas Pharma Inc. (Japan)
14.2.8. AstraZeneca (U.K.)
14.2.9. Auritec Pharmaceuticals Inc. (U.S.)
14.2.10. Bayer AG (Germany)
14.2.11. Chimerix Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
